Cocrystal Pharma (COCP) Cash from Financing Activities (2010 - 2025)

Cocrystal Pharma has reported Cash from Financing Activities for 14 years, with the latest figure at $1.0 million in Q4 2025.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.0 million (changed N/A YoY) and the FY2025 annual result came in at $5.4 million, changed N/A from the prior year.
• Cash from Financing Activities eased to $1.0 million in Q4 2025 per COCP's latest filing, from $4.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $36.4 million in Q2 2021 and troughed at -$11000.0 in Q3 2021.
• A 4-year average of $4.0 million and a median of -$7000.0 in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2021 and 2022: Cash from Financing Activities surged 82879.55% in 2021, then tumbled 100.29% in 2022.
• Over 4 years, Cash from Financing Activities stood at -$9000.0 in 2021, then climbed by 22.22% to -$7000.0 in 2022, then soared by 57242.86% to $4.0 million in 2023, then plunged by 74.2% to $1.0 million in 2025.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $1.0 million, $4.0 million, and -$7000.0 for Q4 2025, Q2 2023, and Q1 2023 respectively.